Vedanta Limited Amended Facility Agreement Upsized to $600 Million

Vedanta Limited has announced an amendment to an existing facility agreement, increasing the total commitment to US$ 600 million. Originally entered into on January 30, 2026, the agreement was updated on May 13, 2026. The proceeds from this facility are designated for the repayment of existing financial indebtedness, general corporate purposes, and the coverage of related fees and expenses for the promoter group’s entities.

Facility Agreement Amendment

Vedanta Limited has confirmed that an existing facility agreement has been amended and restated to increase the total facility amount from US$ 350 million to US$ 600 million. The amended agreement was officially executed on May 13, 2026. While Vedanta Limited itself is not a party to the agreement, the facility involves key promoter group entities acting as borrowers and guarantors.

Purpose of the Financial Arrangement

The capital raised through this amended agreement is intended to support the financial obligations of the promoter group. Key objectives include:

  • Repayment of Financial Indebtedness: Clearing existing debts and accrued interest for the group.
  • Transaction Expenses: Settling fees, costs, and expenses related to the finance documents.
  • General Corporate Purposes: Supporting the broader operational requirements of the group entities.

Management and Control Considerations

The company has clarified that this transaction has no direct impact on the management or control of Vedanta Limited. Although encumbrances have been created over shares held by the promoter group as part of the financing arrangements, these have been duly disclosed in compliance with regulatory standards. The agreement includes standard covenants regarding the company’s asset management, mergers, and financial distributions to ensure the protection of the lending parties.

Source: BSE

Previous Article

Tata Steel FY2026 Consolidated EBITDA Hits Rs 34,848 Crore Amid Operational Excellence

Next Article

Gland Pharma Limited Board Approves Employee Stock Option Grant